NDAORALTABLETPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LODOSYN (carbidopa tablets) by Atonco is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 1977.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LODOSYN (carbidopa tablets) is a DOPA decarboxylase inhibitor approved in 1977 that blocks the peripheral conversion of levodopa, enhancing its CNS availability for Parkinson's disease treatment. It is typically used as an adjunct to levodopa therapy to reduce peripheral side effects and improve motor control. Carbidopa works by inhibiting aromatic amino acid decarboxylation, allowing more levodopa to reach the brain.
LOE Approaching
This is a mature product approaching loss of exclusivity with minimal linked job activity; teams are likely small and focused on margin protection rather than expansion.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Career Relevance
Working on LODOSYN offers limited career acceleration; the product is approaching LOE with minimal linked job creation and faces entrenched competition from superior fixed-dose combinations. Career development is constrained to defensive brand protection, payer negotiations, and generic transition management rather than market expansion or clinical innovation.
Worked on LODOSYN at Atonco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.